Cytokinetics Inc (NAS:CYTK)
$ 47.765 -1.215 (-2.48%) Market Cap: 5.01 Bil Enterprise Value: 5.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 21, 2021 / 06:00PM GMT
Release Date Price: $21.77 (+2.16%)
Dane Leone
Raymond James Financial, Inc. - Analyst

Hi, everyone. Welcome back to the next session here at the Raymond James Human Health Innovation Conference virtual format 2021. My name is Dane Leone; I'm one of the senior biotech analysts on the Ray J team. With me for this session, we will have a fireside chat with the management team of Cytokinetics. I'm extremely pleased to have the CEO, Robert Blum with me, and Fady Malik. It's going to be a great discussion today, do some Q&A.

Before we jump into some of the questions though, I want to hand it over to Robert and Fady to give a brief introduction of themselves. So, Robert, do you want to jump in first -- or, Fady, do you want to start?

Fady Malik
Cytokinetics, Incorporated - EVP, R&D

I'll start first, Dane. Hi, everybody. I'm Fady Malik; I'm the Head of R&D at Cytokinetics, helped launch the Company back in 1998, and I'm a physician-scientist of cardiology background.

Robert Blum
Cytokinetics, Incorporated - President & CEO

Good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot